Management of Elevated PTH in Chronic Kidney Disease

Initial Assessment and Evaluation

The Kidney International guideline recommends measuring serum phosphorus to detect hyperphosphatemia, which drives PTH elevation even when calcium is normal, in patients with CKD stages 3a-5 not on dialysis 1, 3
The American College of Physicians, as published in Annals of Internal Medicine, suggests confirming calcium status with ionized calcium measurement, as total calcium may be misleading, in CKD patients 3
The Kidney International guideline advises checking 25-hydroxyvitamin D levels and supplementing if deficient (target >30 ng/mL) in patients with CKD stages 3a-5 not on dialysis 3
The Kidney International guideline recommends assessing phosphate intake from dietary sources, as high intake can stimulate PTH even without overt hyperphosphatemia, in patients with CKD stages 3a-5 not on dialysis 1, 3

The Kidney International guideline suggests addressing hyperphosphatemia by restricting dietary phosphate intake and initiating phosphate binders if needed, in patients with CKD stages 3a-5 not on dialysis 1, 5
The Kidney International guideline recommends providing calcium supplements and/or calcium-based phosphate binders for hypocalcemia, but restricting doses to avoid hypercalcemia, in patients with CKD stages 3a-5 not on dialysis 1, 5
The Annals of Internal Medicine guideline advises supplementing with native vitamin D (ergocalciferol or cholecalciferol) to achieve levels >30 ng/mL in patients with CKD stages 3a-5 not on dialysis 3

The Kidney International guideline recommends monitoring calcium and phosphate every 6-12 months, and PTH once initially, then based on baseline level and CKD progression, in patients with CKD stages 3a-3b not on dialysis 1
The Kidney International guideline suggests monitoring calcium and phosphate every 3-6 months, and PTH every 6-12 months, in patients with CKD stage 4 not on dialysis 1
The Kidney International guideline advises monitoring calcium and phosphate every 1-3 months, and PTH every 3-6 months, in patients with CKD stage 5 not on dialysis 1

The Kidney International guideline warns that hypercalcemia must be avoided in all CKD stages 3a-5D, and recommends restricting calcium-based phosphate binder doses and reducing or stopping calcitriol/vitamin D analogs if hypercalcemia develops 1, 5
The Annals of Internal Medicine guideline notes that active vitamin D therapy is associated with a 22-43% incidence of hypercalcemia, and recommends close monitoring 3

The Kidney International guideline suggests considering parathyroidectomy for patients with CKD stages 3a-5D who have severe hyperparathyroidism failing medical/pharmacological therapy 1, 2